Jenni Bernoulli

Dr. Jenni Bernoulli


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
TKTiina Kähkönen
Tiina Kähkönen
JHJussi Halleen
Jussi Halleen
JBJenni Bernoulli
Jenni Bernoulli
Immunotherapies provide a potential treatment option for currently incurable bone metastases. Bone marrow is an important secondary lymphoid organ with a unique immune contexture. Even at non-disease state immune cells and bone cells interact with each other, bone cells supporting the development of immune cells and immune cells regulating bone turnover. In cancer, tumor cells interfere with this homeostatic process starting from formation of pre-metastatic niche and later supporting growth of bone metastases. In this review, we introduce a novel concept osteoimmuno-oncology (OIO), which refers to interactions between bone, immune and tumor cells in bone metastatic microenvironment. We also discuss therapeutic opportunities of targeting immune cells in bone metastases, and associated efficacy and safety concerns.

18 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TKTiina Kähkönen
Tiina Kähkönen
JHJussi Halleen
Jussi Halleen
JBJenni Bernoulli
Jenni Bernoulli
Metastases cause high mortality in several cancers and immunotherapies are expected to be effective in the prevention and treatment of metastatic disease. However, only a minority of patients benefit from immunotherapies. This creates a need for novel therapies that are efficacious regardless of the cancer types and metastatic environments they are growing in. Preclinical immuno-oncology models for studying metastases have long been limited to syngeneic or carcinogenesis-inducible models that have murine cancer and immune cells. However, the translational power of these models has been questioned. Interactions between tumor and immune cells are often species-specific and regulated by different cytokines in mice and humans. For increased translational power, mice engrafted with functional parts of human immune system have been developed. These humanized mice are utilized to advance understanding the role of immune cells in the metastatic process, but increasingly also to study the efficacy and safety of novel immunotherapies. From these aspects, this review will discuss the role of immune cells in the metastatic process and the utility of humanized mouse models in immuno-oncology research for metastatic cancers, covering several models from the perspective of efficacy and safety of immunotherapies.

31 January 2022 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
RSRisto Santti
Risto Santti
EYEmrah Yatkin
Emrah Yatkin
JBJenni Bernoulli
Jenni Bernoulli
TSTomi Streng
Tomi Streng
The prevalence of LUTS and prostatic diseases increases with age both in humans and companion animals, suggesting that a common underlying cause of these conditions may be age-associated alterations in the balance of sex hormones. The symptoms are present with different and variable micturition dysfunctions and can be assigned to different clinical conditions including bladder outlet obstruction (BOO). LUTS may also be linked to chronic non-bacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS), but the relationship between these conditions is unknown. This review summarizes the preclinical data that supports a role for excessive estrogen action in the development of obstructive voiding and nonbacterial prostatic inflammation. Preclinical studies that are emphasized in this review have unequivocally indicated that estrogens can induce functional and structural changes resembling those seen in human diseases. Recognizing excessive estrogen action as a possible hormonal basis for the effects observed at multiple sites in the LUT may inspire the development of innovative treatment options for human and animal patients with LUTS associated with functional BOO and CP/CPPS.

2 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TKTiina Kähkönen
Tiina Kähkönen
JWJie Wen
Jie Wen
RYRu Yang
Ru Yang
YXYuyang Xu
Yuyang Xu
JBJenni Bernoulli
Jenni Bernoulli
JHJussi Halleen
Jussi Halleen
Background/Objectives: Triple-negative breast cancer (TNBC), castration-resistant pros-tate cancer (CRPC), and multiple myeloma (MM) are common cancers associated with high incidence of bone metastases, leading to high mortality, severe pain and reduced quality of life. Preclinical drug development in these cancers typically focuses solely on primary tumors, overlooking the critical bone metastatic tumor microenvironment that plays a key role in the unique aspects of osteo-immuno-oncology, highlighting the need for clinically predictive bone metastasis models. The aim of this study was to establish preclinical models that represent clinical features of bone metastases in patients and serve as predictive tools to drive drug development. Methods: TNBC, CRPC and MM cells were inoculated into the bone marrow of mice. Tumor growth was monitored by biolumines-cence imaging (BLI), cancer-induced bone loss by scoring X-ray images, and bone pain by von Frey filaments. Results: All mice developed bone metastases, with high tumor burden observed at days 21, 28, and 56 in the TNBC, CRPC, and MM models, respectively. Tu-mor-induced osteolytic, osteoblastic or mixed bone changes closely resembled those seen in patients. Bone pain, a key indicator of quality of life, correlated with tumor burden and bone loss. Conclusions: The established preclinical models accurately represent clinical features, including tumor-induced bone changes and pain, that are observed in bone met-astatic TNBC, CRPC and MM patients. Given their clinical presentation, these models should be integrated into drug development to reliably assess novel therapies in these in-dications, with a proper focus on bone metastases.